Skip to main content
MANGALAM · Health Care · 2026-08-07

Mangalam Drugs and Organics Ltd

Stage 4 · wk 18In scan: Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹27.2
+0.67% today
₹43 Cr · Micro cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base; and tenofovir disoproxil base. In addition, the company offers specialty chemicals comprising l(+)menthol; 2,3-dihydrophthalazine-1, 4-dione or phthalazine-1,4-dione; and 4-cynoethyl-2-methy phenol. Further, it manufactures organic and inorganic chemicals, and heavy chemicals. Additionally, it offers active pharmaceutical ingredients; and products covering various therapeutic areas comprising anti-malaria, anti-retroviral, anti-hypertensive, anti-inflammatory, anti-convulsant, anti-viral, anti-rheumatic arthritis agents, and anti-bacterial, as well as develops product for anti-hypertensive indications. Mangalam Drugs & Organics Limited was incorporated in 1972 and is based in Mumbai, India.

Visit company website →
ROE
-35.2%
Profit margin -19.1%
vs 52W High
-69.7%
₹23.8 lo₹89.7 hi
69.7% below 52W high — deep Stage 4 damage
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 18
1w13w26w
Week 18 — established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-21.8%
200 DMA: ₹34.8 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
0.93x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
MA20 rolling over · -1.4% vs MA50 -3.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
Sector has 79 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Industry has 53 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-12 → 2026-08-07
S4 22w
S2 18w
S4 20w
S4 25w
S4 18w
2023-05-122026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 1w → S1 1w → S4 6w → S1 1w → S4 1w → S1 1w → S4 6w → S1 2w → S4 22w → S1 3w → S2 6w → S3 5w → S4 5w → S1 2w → S2 18w → S3 11w → S4 20w → S1 12w → S4 25w → S1 5w → S4 18w current
Total tracked: 168 weeks across 21 stage runs.
1M
-0.3%
3M
-10.3%
6M
-24.7%
YTD
+14.3%
1Y
-69.6%
Scan Membership
Breakout Watch
Latest: 2024-07-05
2 appearances in last 60 days. First seen: 2024-02-21.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S4
Wk 18 · Vol x
2026-08-06S4
Wk 18 · Vol x
2026-08-05S4
Wk 17 · Vol x
2026-08-04S4
Wk 17 · Vol x
2026-08-03S4
Wk 17 · Vol x
2026-07-31S4
Wk 17 · Vol x
2026-07-30S4
Wk 17 · Vol x
2026-07-29S4
Wk 16 · Vol x
2026-07-28S4
Wk 16 · Vol x
2026-07-27S4
Wk 16 · Vol x
2026-07-24S4
Wk 16 · Vol x
2026-07-23S4
Wk 16 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹28.1
200 DMA
₹34.8
52W High
₹89.7
52W Low
₹23.8
5D Low
₹27
Resistance levels (recent highs)
20d High
₹28
60d High
₹30.8
120d High
₹34.6
250d High
₹89.7
Next resistance
+2.9%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.